Evofem Biosciences (NASDAQ:EVFM – Get Free Report) and Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, profitability and dividends.
Insider and Institutional Ownership
0.2% of Evofem Biosciences shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 0.2% of Evofem Biosciences shares are held by company insiders. Comparatively, 4.1% of Fulcrum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of recent recommendations and price targets for Evofem Biosciences and Fulcrum Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evofem Biosciences | 0 | 1 | 0 | 0 | 2.00 |
| Fulcrum Therapeutics | 0 | 0 | 7 | 0 | 3.00 |
Profitability
This table compares Evofem Biosciences and Fulcrum Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evofem Biosciences | 315.54% | -81.10% | 437.75% |
| Fulcrum Therapeutics | -3,470.05% | -40.60% | -37.19% |
Earnings & Valuation
This table compares Evofem Biosciences and Fulcrum Therapeutics’ revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evofem Biosciences | $18.22 million | 0.05 | $52.98 million | ($5.93) | 0.00 |
| Fulcrum Therapeutics | $2.81 million | 137.13 | -$97.33 million | ($1.60) | -3.87 |
Evofem Biosciences has higher revenue and earnings than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Evofem Biosciences has a beta of -0.65, suggesting that its stock price is 165% less volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.34, suggesting that its stock price is 134% more volatile than the S&P 500.
Summary
Fulcrum Therapeutics beats Evofem Biosciences on 9 of the 14 factors compared between the two stocks.
About Evofem Biosciences
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
About Fulcrum Therapeutics
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
